Gil Roth12.09.13
QLT Inc. has dosed the first patient has been dosed in the Phase IIa proof-of-concept trial of QLT091001 in adult subjects with Impaired Dark Adaptation (IDA), a condition that results in decreased ability to recover visual sensitivity in the dark after exposure to bright lights.
The randomized, multi-center, parallel-group, placebo-controlled trial covers subjects (age 60 or older) with IDA, or impaired low luminance low contrast best corrected visual acuity (LLLC BCVA) in at least one eye and having no known ophthalmic pathologies to explain their condition other than early age-related macular degeneration (AMD). Patients will be enrolled at sites in the U.S. Subjects will be randomized to receive placebo or one of two different doses (10 or 40 mg/m2) of QLT091001 once per week for three consecutive weeks with one additional dose the day after the third dose. The trial is designed to evaluate the safety profile and effects of QLT091001 on impaired dark adaptation time, glare recovery time and LLLC BCVA.